A new study shows that detecting and isolating Clostridium difficile carriers when they are admitted to hospitals can significantly reduce the incidence of new infections from the pathogen.
With the battle against healthcare associated infections seemingly under-armed against drug-resistant pathogens, the medical community is increasingly emphasizing preventive measures against the spread of “superbugs.” A new study shows that detecting and isolating Clostridium difficille (C. difficile) carriers when they are admitted to hospitals can significantly reduce the incidence of new infections from the pathogen.
The study, published in the journal JAMA Internal Medicine, was performed by researchers from Canada and Israel. According to another study by the Centers for Disease Control and Prevention, there are nearly half a million cases of C. difficile infections (CDI) in the United States each year, with about 15,000 deaths directly links to these infections. Stopping the antibiotic-resistant pathogen has become a healthcare priority worldwide due to the number of patients presenting with these difficult-to-treat infections.
Apart from those with active infections, there are a number of people who are asymptomatic C. difficile carriers, having no symptoms of infection from the bacteria while still having the spores present in their feces. C. difficile colonization is more common than C. difficile infection. Because carriers can present a health risk to non-carriers in a hospital setting, the authors of this study wanted to investigate the effect of detecting and isolating C. difficile asymptomatic carriers at hospital admission on the incidence of healthcare associated CDI (HA-CDI). The screening effort is similar to the preemptive approach by some healthcare facilities to test new hospital patients for other drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus.
In this quasi-experimental study conducted in a Canadian acute care facility between November 2013 and March 2015, the researchers did rectal swabs on incoming patients to test for the presence of the toxin gene tcdB produced by C. difficile. A total of 7599 eligible patients were screened, with a total of 368 patients identified as C. difficile carriers through testing. Once identified, the carriers were placed under contact isolation precautions apart from non-carriers during their hospital stay. Over the course of the intervention period, 38 patients developed an HA-CDI. This was compared to a pre-intervention control period in which 416 patients developed an HA-CDI. The incidence rate of HA-CDI decreased by more than 50% to 3.0 per 10,000 patient days compared to 6.9 per 10,000 patient days before the intervention. Based on the researcher’s estimates, the intervention of testing and isolation prevented 63 of the expected 101 cases of HA-CDI.
The authors note that the findings need to be confirmed with additional studies, as the study was limited by the fact that it was only conducted at one center. Still, the research offers a promising preventive approach to curtailing the spread of C. difficile and reducing the number of these healthcare associated infections each year. “Detecting and isolating C. difficile carriers was associated with a significant decrease in the incidence of HA-CDI,” write the study authors. “If confirmed in subsequent studies, this strategy could help prevent HA-CDI.”
To prevent the spread of C. difficile in hospitals and healthcare facilities, the CDC recommends the following steps that healthcare professionals can take: